Avelumab
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Epithelial Cancer of Ovary
Conditions
Recurrent Epithelial Cancer of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Trial Timeline
Nov 9, 2017 → Mar 19, 2019
NCT ID
NCT03312114About Avelumab
Avelumab is a phase 2 stage product being developed by AstraZeneca for Recurrent Epithelial Cancer of Ovary. The current trial status is terminated. This product is registered under clinical trial identifier NCT03312114. Target conditions include Recurrent Epithelial Cancer of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03312114 | Phase 2 | Terminated |
Competing Products
20 competing products in Recurrent Epithelial Cancer of Ovary